These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30573201)
1. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. White MN; Dotan E; Catalano PJ; Cardin DB; Berlin JD J Geriatr Oncol; 2019 Jul; 10(4):540-546. PubMed ID: 30573201 [TBL] [Abstract][Full Text] [Related]
2. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. Rahib L; Fleshman JM; Matrisian LM; Berlin JD JAMA Oncol; 2016 Sep; 2(9):1209-16. PubMed ID: 27270617 [TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
6. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038 [TBL] [Abstract][Full Text] [Related]
7. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826 [TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697 [TBL] [Abstract][Full Text] [Related]
9. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797 [TBL] [Abstract][Full Text] [Related]
10. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Miller RC; Iott MJ; Corsini MM Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):364-8. PubMed ID: 19735864 [TBL] [Abstract][Full Text] [Related]
11. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971 [TBL] [Abstract][Full Text] [Related]
12. Metastatic gastroesophageal cancer in older patients - is this patient cohort represented in clinical trials? Hennessy MA; Hamid M; Keegan NM; Corrigan L; Goggin C; Oo NM; Carrigan M; Mockler D; O'Donovan A; Horgan AM BMC Cancer; 2022 Jan; 22(1):3. PubMed ID: 34980003 [TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061 [TBL] [Abstract][Full Text] [Related]
15. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853 [TBL] [Abstract][Full Text] [Related]
16. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442 [TBL] [Abstract][Full Text] [Related]
17. [The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review]. Azria D; Seblain-El-Guerche C; Girard N; Hennequin C; Huguet F Bull Cancer; 2008 Nov; 95(11):1116-30. PubMed ID: 19036684 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197 [TBL] [Abstract][Full Text] [Related]
20. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Sgouros J; Maraveyas A Acta Oncol; 2008; 47(3):337-46. PubMed ID: 17957501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]